Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,868 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: Short Bowel Syndrome
Interventions: Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection; Drug · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Duchenne Muscular Dystrophy
Interventions: HT-100; Drug
Lead sponsor: Akashi Therapeutics; Industry
Eligibility: 6 Years to 20 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Heart Diseases, Left Ventricular Dysfunction
Interventions: Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure; Drug · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 30 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Parkinson's Disease
Interventions: Skill-Based Exercise, Aerobic Exercise, Social Contact; Other
Lead sponsor: University of Southern California; Other
Eligibility: 30 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neurofibromatosis Type 1
Interventions: Selumetinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Rochester, Minnesota • Akron, Ohio

Conditions: Diabetes (DM)
Interventions: Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution; Drug
Lead sponsor: David D'Alessio, M.D.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Lymphoblastic Leukemia
Interventions: Gross Motor Function, Knee extension strength, Hand grip strength, Flexibility, Ankle range of motion, Aerobic capacity, Body composition and vital signs; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 10 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Portland, Oregon • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more

Conditions: Hospital Acquired Condition
Interventions: CONCERN CDS system notification; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 60,893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Newton, Massachusetts • New York, New York

Conditions: Blood Pressure, Hypertension
Interventions: Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Type 2 Diabetes
Interventions: Control-IQ use in Type 2 Diabetes under basal insulin injections; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Appetitive Behavior, Obesity
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), Sham repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Belmont, Massachusetts • Boston, Massachusetts

Conditions: Osteoporosis
Interventions: Metabolic / prescribed diet, KCit Load (40 meq), Anti-resorptive agents, Anabolic Agents; Other · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Smoking Cessation
Interventions: Nicotine patch, Behavioral counseling; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: Intervention Group, Control Group; Behavioral
Lead sponsor: BETH COMERFORD; Other
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Healthy Participants
Interventions: Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Adult, Traumatic Brain Injury, fMRI
Interventions: Elliptical exercise; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 44 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer
Interventions: H002; Drug
Lead sponsor: RedCloud Bio; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Gestational Diabetes, Pregnancy, Glucose Intolerance
Interventions: Gestational diabetes screening with fasting 3 hour 100 gm, Gestational diabetes screening with fasting 2 hour 75g; Diagnostic Test
Lead sponsor: Esa M Davis, MD MPH FAAFP; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 921 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Drug Interactions
Interventions: Fexofenadine, Telotristat etiprate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Lofexidine HCl; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease, Lymphoma
Interventions: EBV-specific T cells: A, EBV-specific T cells: B; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Neonatal Opioid Withdrawal Syndrome
Interventions: Morphine, Methadone; Drug
Lead sponsor: Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program; Network
Eligibility: 36 Weeks and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 18 more

Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions: BGB-21447, Fulvestrant, BGB-43395; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Iowa City, Iowa • Houston, Texas • Seattle, Washington

Conditions: Type 2 Diabetes
Interventions: Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels; Other
Lead sponsor: Foundation for Atlanta Veterans Education and Research, Inc.; Other
Eligibility: 40 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Search by objective public record fields.

rHGH and Intestinal Permeability in Intestinal Failure

HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

Exercise Targeting Cognitive Impairment in Parkinson's Disease

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

Aerobic and Strengthening Exercise for Acute Leukemia

(CONCERN) Clinical Decision Support (CDS) System

Reversing Glucose and Lipid-mediated Vascular Dysfunction

Automated Insulin Delivery (AID) for Basal Insulin Titration in Type 2 Diabetes

Validation of a Novel Cerebellar-striatal Satiety Circuit in Humans

Contribution of Bone to Urine Citrate

Cognition and Smoking Relapse (HCS)

Fruit and Vegetable Prescription Program

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

Effects of Rapid-Resisted Exercise and Bright Light Therapy on Ambulatory Adults With Traumatic Brain Injury

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

Lofexidine Food Effect Study in Healthy Volunteers

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)